Syneron Inc. to Present at Two Upcoming Conferences

YOKNEAM, ISRAEL--(Marketwire - September 13, 2011) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that Louis P. Scafuri, Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the annual UBS Global Life Sciences Conference in New York City.

Event: UBS Global Life Sciences Conference
Date: Monday, September 19, 2011
Time: 9:30 a.m. ET

The second presentation will be at the JMP Securities Healthcare Conference in New York City.

Event: JMP Securities Healthcare Conference
Date: Wednesday, September 28, 2011
Time: 10:00 a.m. ET

The presentations will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron’s website at www.syneron.com. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets and services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.